These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26842236)

  • 1. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
    Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
    Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
    Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
    Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.
    Cecchini M; Walther Z; Wei W; Hafez N; Pilat MJ; Boerner SA; Durecki DE; Eder JP; Schalper KA; Chen AP; LoRusso P
    Cancer Res Commun; 2023 Jun; 3(6):1113-1117. PubMed ID: 37377610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
    Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
    Tan AR; Chan N; Kiesel BF; Stein MN; Moss RA; Malhotra J; Aisner J; Shah M; Gounder M; Lin H; Kane MP; Lin Y; Ji J; Chen A; Beumer JH; Mehnert JM
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):49-58. PubMed ID: 34669023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
    Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
    Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
    Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
    LaRose M; Connolly RM; O'Sullivan CC; Velcheti V; Vilimas R; Gano K; Bates SE; Pommier Y; Thomas A
    Oncologist; 2023 May; 28(5):460-e298. PubMed ID: 37010988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    Villalona-Calero MA; Duan W; Zhao W; Shilo K; Schaaf LJ; Thurmond J; Westman JA; Marshall J; Xiaobai L; Ji J; Rose J; Lustberg M; Bekaii-Saab T; Chen A; Timmers C
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26848151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
    Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
    Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
    [No Abstract]   [Full Text] [Related]  

  • 15. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
    Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
    J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
    Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
    Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
    Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
    Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
    Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
    Berlin J; Ramanathan RK; Strickler JH; Subramaniam DS; Marshall J; Kang YK; Hetman R; Dudley MW; Zeng J; Nickner C; Xiong H; Komarnitsky P; Shepherd SP; Hurwitz H; Lenz HJ
    Br J Cancer; 2018 Apr; 118(7):938-946. PubMed ID: 29527010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.